MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.3263

Медицинская библиотека · European journal of heart failure · 2024

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

Yang Mingming, Kondo Toru, Talebi Atefeh, Jhund Pardeep S, Docherty Kieran F, Claggett Brian L, Vaduganathan Muthiah, Bachus Erasmus, Hernandez Adrian F, Lam Carolyn S P, Inzucchi Silvio E, Martinez Felipe A, de Boer Rudolf A, Kosiborod Mikhail N, Desai Akshay S, Køber Lars, Ponikowski Piotr, Sabatine Marc S, Solomon Scott D, McMurray John J V

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

AIMS: Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of health-related quality of life (HRQL) in HF. The aim of this study was to assess the relationship between the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analogue scale (VAS) and index scores, clinical characteristics, and outcomes in patients with HF and the effect of dapagliflozin on these scores.

METHODS AND

RESULTS

We performed a patient-level pooled analysis of the DAPA-HF and DELIVER trials, which investigated the effectiveness and safety of dapagliflozin in patients with HF and reduced ejection fraction (HFrEF) and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), respectively. Patients reporting higher (better) EQ-5D-5L VAS and index scores had a lower prevalence of comorbidities, including atrial fibrillation and hypertension, than patients with a worse score. They were also more likely to have better investigator-reported (New York Heart Association class) and patient-self-reported (Kansas City Cardiomyopathy Questionnaire) health status and lower median N-terminal pro-B-type natriuretic peptide levels. Compared to patients with the lowest scores (Q1), those with higher EQ-5D-5L VAS scores had better outcomes: the hazard ratio for the composite of cardiovascular death or worsening HF was 0.81 (95% confidence interval 0.72-0.91) in Q2, 0.74 (0.65-0.84) in Q3, and 0.62 (0.54-0.72) in Q4. The risk of each component of the composite outcome, and all-cause death, was also lower in patients with better scores. Similar findings were observed for the index score. Treatment with dapagliflozin improved both EQ-5D-5L VAS and index scores across the range of ejection fraction.

CONCLUSIONS

Both higher (better) EQ-5D-5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ-5D-5L VAS and index scores, irrespective of ejection fraction.

Для цитирования: Yang Mingming, Kondo Toru, Talebi Atefeh, Jhund Pardeep S, Docherty Kieran F, Claggett Brian L, Vaduganathan Muthiah, Bachus Erasmus, Hernandez Adrian F, Lam Carolyn S P, Inzucchi Silvio E, Martinez Felipe A, de Boer Rudolf A, Kosiborod Mikhail N, Desai Akshay S, Køber Lars, Ponikowski Piotr, Sabatine Marc S, Solomon Scott D, McMurray John J V. Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.. European journal of heart failure. 2024. DOI: 10.1002/ejhf.3263.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.